Glenmark Pharmaceuticals is seeking shareholders’ approval to raise up to $500 million (around Rs 3,300 crore) by issue of securities in domestic and international markets.
In order to capitalise on various opportunities for further growth of the business, the company intends to enhance its marketing network both in domestic and overseas market, set up manufacturing infrastructure, focus on R&D and introduce new products across various markets.